Sotatercept, Fixed-Dose Combo Therapy on the Right Path for PAH
NEW ORLEANS — The limited clinical evidence thus far supports investigational compounds for addition to or simplification of existing frontline therapies for pulmonary arterial hypertension (PAH), according to two trials presented here at the American College of Cardiology (ACC) annual meeting. The activin signaling inhibitor biologic sotatercept showed promise as an add-on to usual treatment […]